Biocartis Group (LSE:0R72) - Aandelenkoers, Nieuws & Analyse

0R72 Overzicht aandelen

A molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Meer informatie

0R72 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 22.28% per jaar groeien

Risicoanalyse

De winst is de afgelopen 5 jaar met 7.1% per jaar gedaald

Heeft minder dan 1 jaar cash runway

Negatief eigen vermogen

Aandelen zijn zeer illiquide

+ 2 meer risico's

Biocartis Group NV Concurrenten

Ondine Biomedical

AIM:OBI

UK£22.9m

Polarean Imaging

AIM:POLX

UK£18.7m

Inspiration Healthcare Group

AIM:IHC

UK£14.1m

ANGLE

AIM:AGL

UK£33.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Biocartis Group
Historische aandelenkoersen
Huidige aandelenkoers	€0.30
52 Week Hoogtepunt	€0.76
52 Week Laag	€0.30
Bèta	1.38
11 maand verandering	0%
3 maanden verandering	4.00%
1 Jaar Verandering	-43.90%
33 jaar verandering	-93.57%
5 jaar verandering	-97.01%
Verandering sinds IPO	-97.88%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0R72	GB Medical Equipment	GB Markt
7D	0%	-0.2%	2.2%
1Y	-43.9%	-2.4%	8.8%

Rendement versus industrie: 0R72 presteerde slechter dan de UK Medical Equipment -sector, die het afgelopen jaar een rendement van -2.4 % opleverde.

Rendement versus markt: 0R72 presteerde slechter dan UK Market, dat het afgelopen jaar een rendement van 8.8 % opleverde.

Prijsvolatiliteit

Is 0R72's price volatile compared to industry and market?
0R72 volatility
0R72 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.3%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: 0R72 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 0R72 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	526	Roger Moody	www.biocartisgroupnv.be

Biocartis Group NV Samenvatting

Hoe verhouden de winst en inkomsten van Biocartis Group zich tot de beurswaarde?
0R72 fundamentele statistieken
Marktkapitalisatie	€27.24m
Inkomsten(TTM)	-€67.87m
Inkomsten(TTM)	€60.82m

0.4x

P/S-verhouding

-0.4x

Koers/Winstverhouding

Is 0R72 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0R72 resultatenrekening (TTM)
Inkomsten	€60.82m
Kosten van inkomsten	€65.51m
Brutowinst	-€4.69m
Overige uitgaven	€63.18m
Inkomsten	-€67.87m

Laatst gerapporteerde inkomsten

Jun 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.72
Brutomarge	-7.71%
Nettowinstmarge	-111.58%
Schuld/Eigen Vermogen Verhouding	-257.9%

Hoe presteerde 0R72 op de lange termijn?

Bekijk historische prestaties en vergelijking

0R72 Overzicht aandelen

Beloningen

Risicoanalyse

Biocartis Group NV Concurrenten

AIM:OBI

UK£22.9m

AIM:POLX

UK£18.7m

AIM:IHC

UK£14.1m

AIM:AGL

UK£33.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Biocartis Group Ordinary Shares to be Deleted from OTC Equity

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

First half 2023 earnings released

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

Recent updates

Biocartis Group Ordinary Shares to be Deleted from OTC Equity

Biocartis Group NV Presents Four Abstracts Showing Excellent Data for Idylla at European Society of Molecular Oncology Congress

First half 2023 earnings released

Biocartis Appoints New Medical Advisory Board (Mab) of Renowned Practice Leaders

Biocartis Group NV to Report First Half, 2023 Results on Sep 26, 2023

Biocartis Group NV Appoints George Cardoza as Chief Financial Officer, Effective 7 August 2023

New minor risk - Share price stability

Biocartis Group NV Announces Resignation of Jean-Marc Roelandt as CFO

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Full year 2022 earnings released: €0.79 loss per share (vs €1.24 loss in FY 2021)

Biocartis Group NV Announces the Launch of the First Assay Developed With the New Idylla™ Flex Technology

Biocartis Group NV has completed a Follow-on Equity Offering in the amount of €25.107699 million.

Insufficient new directors

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV Announces New Idylla™ EGFR Study Shows Reduction of Time-To-Treatment by 48% for Lung Cancer Patients

Biocartis Group NV to Report Q1, 2023 Results on Apr 20, 2023

First half 2022 earnings released: EPS: €0 (vs €0.65 loss in 1H 2021)

Biocartis Group NV Provides Earnings Guidance for 2022

Biocartis Group NV Obtains ISO 27001 Certification for Information Security Management

Biocartis Group NV Announces Launch of its Rapid CE-marked IVD Idylla GeneFusion Panel for Fast Treatment Decisions in Lung Cancer

Biocartis Group NV announces New Study Led by Memorial Sloan Kettering Cancer Center (NY, US) Shows Idylla™ Genefusion Assay Enables More Rapid Screening of Targetable Fusions Compared to Routine Methods

Insufficient new directors

Biocartis Group NV Reconfirms Earnings Guidance of 2022

Full year 2021 earnings released: €1.24 loss per share (vs €1.11 loss in FY 2020)

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Biocartis Group NV Provides Earnings Guidance for the Year 2022

Biocartis Group NV Announces Publication of Large New Study Comparing the Difference in Turnaround Time Between In-House Automated Rapid Pcr3-Based EGFR Analysis and Next-Generation Sequencing

Insufficient new directors

Biocartis’ Idylla™ SARS-CoV-2 Testing Successfully Detects Omicron Variant

Biocartis Group NV Announces Restart of Its High-Throughput Cartridge Manufacturing Line

Biocartis Group NV Receives EUR 1.4 Million Grant to Support Development of New Idylla™ Technology

Biocartis Group NV Reconfirms Production Guidance of 2021

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

New 90-day low: €4.38

Full year 2020 earnings released: €1.11 loss per share (vs €1.14 loss in FY 2019)

Revenue beats expectations

Biocartis Group NV Announces Ten Idylla™ Studies to be Published at Virtual AMP (US) Annual Meeting

Biocartis Group NV Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay

Biocartis Group NV to Report Q3, 2021 Results on Nov 10, 2021

Biocartis and Geneprodx to Collaborate on Fully Automated Thyroidprint Test on Idylla

Biocartis Group NV Announces Partnership with Endpoint Health to Develop Novel Companion Diagnostic in Critical Illness

New 90-day low: €4.15

Biocartis Group Nv Announces Market Release of Septicyte® Rapid Test on Idylla™

First half earnings released

Biocartis Group NV to Report Fiscal Year 2020 Final Results on Apr 01, 2021

New 90-day high - €5.03

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Biocartis Group NV Samenvatting

0.4x

-0.4x

Inkomsten en omzet